IRVINE, Calif., Sept. 25, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque and to safely improve lipid profiles in humans, today announced that Chairman and CEO, Thomas W. Gardner, will present a corporate overview at the 2012 Aegis Capital Healthcare Conference. The presentation will take place at 1:45pm PT on Friday, September 28, 2012 at The Wynn in Las Vegas, NV.
Mr. Gardner will discuss exciting near term milestones for AHRO-001, the Company's lead compound for the regression of atherosclerotic plaque, as well as the Company's pipeline and development plans.
In addition to the presentation, Mr. Gardner will be available to meet with analysts, industry executives and investors in one-on-one meetings. Those interested in meeting with Mr. Gardner during the Conference are encouraged to contact the Company directly at firstname.lastname@example.org.
AtheroNova Inc. is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention. www.AtheroNova.com
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding the Company's pipeline, milestones and the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE AtheroNova Inc.